GOSS · Gossamer Bio, Inc. · Documents

Feb 19

Current report 8-K

Other events

Nov 7

Current report 8-K

Financial results

Nov 7

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Revenue $9.48M Net loss $30.8M Diluted EPS -$0.14

Sep 13

Current report 8-K Events of Sep 11

Delisting notice or listing transfer

Aug 12

Current report 8-K

Financial results

Aug 12

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $95.84M Net income $49.23M Diluted EPS $0.22

Jul 18

Current report 8-K

Other events

Jun 10

Current report 8-K Events of Jun 6

Shareholder vote results

May 24

Current report 8-K Events of May 22

Delisting notice or listing transfer

May 7

Current report 8-K

Financial results

May 7

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Net loss $41.93M Diluted EPS -$0.19

May 6

Current report 8-K Events of May 3

Entered into a material agreement, Ended a material agreement, Unregistered sale of equity, Other events

Apr 26

Annual report to holders ARS

Annual report to holders

Apr 24

Proxy statement DEF 14A

Proxy statement

Apr 24

Proxy statement DEFA14A

Proxy statement

Mar 12

Current report 8-K Events of Mar 11

Director or officer change, or executive pay

Mar 5

Current report 8-K

Financial results

Mar 5

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Net loss $179.82M Diluted EPS -$1.18

Mar 4

Current report 8-K

Other events

Nov 29

Current report 8-K Events of Nov 28

Director or officer change, or executive pay

Nov 27

Current report 8-K Events of Nov 20

Director or officer change, or executive pay, Charter or bylaw amendment, or fiscal year change

Nov 9

Current report 8-K

Financial results

Nov 9

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Net loss $40.01M Diluted EPS -$0.21

Oct 20

Current report 8-K Events of Oct 19

Delisting notice or listing transfer

Sep 7

Current report 8-K Events of Sep 6

Director or officer change, or executive pay

Aug 18

Registration statement S-3

Registration statement

Aug 17

Registration statement S-3ASR

Registration statement

Aug 8

Current report 8-K

Financial results

Aug 8

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Net loss $42.5M Diluted EPS -$0.45

Jul 20

Current report 8-K

Other events

Jul 20

Current report 8-K Events of Jul 19

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure

Jun 9

Current report 8-K Events of Jun 8

Charter or bylaw amendment, or fiscal year change, Shareholder vote results

May 9

Current report 8-K

Financial results

May 9

Quarterly report 10-Q FY2023 Q1, ended Mar 31

Quarterly report for FY2023 Q1

Net loss $49.17M Diluted EPS -$0.52

May 9

Proxy statement DEFA14A

Proxy statement

Apr 28

Proxy statement DEF 14A

Proxy statement

Apr 28

Annual report to holders ARS

Annual report to holders

Apr 28

Proxy statement DEFA14A

Proxy statement

Apr 17

Proxy statement PRE 14A

Proxy statement

Apr 3

Current report 8-K

Other events

Mar 17

Current report 8-K

Financial results

Mar 17

Annual report 10-K FY2022, ended Dec 31

Annual report for FY2022

Net loss $229.38M Diluted EPS -$2.71

Dec 6

Current report 8-K

Other events

Nov 3

Current report 8-K

Financial results

Nov 3

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Net loss $59.36M Diluted EPS -$0.65

Aug 9

Current report 8-K

Financial results

Aug 9

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Net loss $56.47M Diluted EPS -$0.74

Aug 9

Registration statement S-3ASR

Registration statement

Jul 13

Current report 8-K

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure

Jun 10

Current report 8-K Events of Jun 9

Shareholder vote results